Active pharmaceutical ingredient (API) manufacturer YUNG ZIP CHEMICAL reported lower revenue and gross margin in the first half of the year, resulting in a net loss of NT$0.19 per share. CEO Yu-Ju Li attributed the decline to early stockpiling of APIs by new drug clients in Phase 3 clinical trials and inventory adjustments by certain customers. He expects some orders to be replenished in the second half, offering a potential revenue rebound. Regarding tariff impacts, Li noted that U.S. tariff policies have not only made American buyers more cautious, but have also prompted some Chinese suppliers to seek other markets, increasing short-term competitive pressure globally.
Read more
